GI medications: a complete nursing reference

Introduction

Gastrointestinal medications are among the highest-yield drug classes on NCLEX and among the most commonly administered drugs in clinical practice. Nurses give acid reducers, antiemetics, laxatives, and antidiarrheals on nearly every shift — which means understanding their mechanisms, timing, and safety concerns is foundational nursing knowledge. Getting the pharmacology right matters: many GI drugs have serious interactions, black box warnings, or contraindications that are easy to miss without a solid framework.

This reference covers every major GI drug class: proton pump inhibitors, H2 blockers, antacids, antiemetics, bowel management agents, motility drugs, antispasmodics, and H. pylori regimens. Each section includes mechanism, key nursing considerations, and NCLEX-priority safety alerts.

Quick reference table

Acid-reducing medications

Acid reduction is one of the most common therapeutic goals in GI nursing. Three drug classes accomplish it through different mechanisms — PPIs provide the most profound and sustained suppression, H2 blockers offer moderate relief, and antacids act quickly but briefly.

Proton pump inhibitors (PPIs)

PPIs are the gold-standard treatment for GERD, peptic ulcer disease, erosive esophagitis, and H. pylori eradication regimens. They work by irreversibly inhibiting the H+/K+ ATPase enzyme (“proton pump”) in parietal cells — meaning acid secretion is blocked until the body synthesizes new pumps, which takes 18–24 hours. This is why PPIs provide 24-hour acid suppression after a single dose.

Common PPIs: omeprazole (Prilosec), pantoprazole (Protonix), lansoprazole (Prevacid), esomeprazole (Nexium).

Nursing considerations:

• Timing: Administer 30–60 minutes before the first meal of the day. Proton pumps are most active when stimulated by food. Taking PPIs without food significantly reduces their effectiveness.
• IV pantoprazole is the most common inpatient formulation; it does not require pre-meal timing.
• Long-term risks: Regular use beyond 8 weeks carries risks that nurses must monitor:
  • Clostridium difficile (C. diff): Reduced gastric acid allows C. diff spores to survive transit through the stomach. Monitor for new-onset diarrhea, especially in hospitalized patients.
  • Hypomagnesemia: PPIs impair magnesium absorption over time. Monitor Mg²⁺ levels in long-term users; symptoms include muscle cramps, tremors, and dysrhythmias.
  • Bone fractures: Long-term PPI use is associated with reduced calcium absorption and increased risk of hip, wrist, and spine fractures. Especially relevant in older patients.
  • Vitamin B12 deficiency: Gastric acid is required for B12 absorption from food. Long-term suppression can lead to deficiency — monitor in patients on PPIs for years.
• Drug interactions: PPIs inhibit CYP2C19 and can increase levels of drugs metabolized by this enzyme, including clopidogrel (Plavix). The interaction with clopidogrel is clinically significant — reduced antiplatelet effect increases cardiovascular risk. See cardiovascular medications nursing reference for more on clopidogrel management.
• Patient teaching: Take 30 minutes before breakfast. Do not crush enteric-coated formulations (omeprazole, esomeprazole) — swallow whole. These can be opened and sprinkled on applesauce, but not crushed or chewed. Report new diarrhea, muscle cramping, or signs of infection.

For a full discussion of GERD pathophysiology and nursing management, see the GERD nursing reference.

H2 receptor blockers

H2 blockers competitively block histamine H2 receptors on parietal cells, reducing cAMP production and, consequently, gastric acid output. They are less potent than PPIs but provide faster symptom relief and are useful for breakthrough heartburn, OTC management, or situations where a PPI is not appropriate.

Common H2 blockers: famotidine (Pepcid). Note: ranitidine (Zantac) was withdrawn from the US market in 2020 due to NDMA contamination concerns. It is no longer approved by the FDA. Famotidine is the primary H2 blocker in current clinical use.

Nursing considerations:

• Famotidine requires renal dose adjustment in patients with CrCl < 50 mL/min — accumulation can cause CNS effects (confusion, agitation) in renal patients.
• H2 blockers can be taken with or without food.
• They do not require pre-meal timing like PPIs.
• Tolerance (tachyphylaxis) can develop within 2 weeks of continuous use — H2 blockers become less effective over time.
• Preferred over PPIs for short-term, on-demand heartburn management. PPIs are preferred for sustained acid suppression in peptic ulcer disease and GERD.

PPI vs H2 blocker comparison:

Antacids

Antacids neutralize existing gastric acid through a chemical buffering reaction — they do not reduce acid production. Their onset is within minutes, but their duration is short (30–60 minutes on an empty stomach, up to 3 hours if taken after meals).

Common antacids: calcium carbonate (Tums), aluminum hydroxide, magnesium hydroxide (milk of magnesia), combination products (Mylanta, Maalox), simethicone (for gas relief).

Nursing considerations:

• Drug interactions are the highest-priority nursing concern. Antacids alter gastric pH and can chelate (bind) other drugs, reducing their absorption significantly. Separate antacids from other oral medications by at least 1–2 hours. Affected drugs include: fluoroquinolones, tetracyclines, iron supplements, thyroid medications, and azole antifungals.
• Aluminum-based antacids tend to cause constipation. Magnesium-based antacids tend to cause diarrhea. Combination products (Al + Mg) balance these effects.
• Calcium carbonate provides a calcium dose — relevant in patients with hypercalcemia or nephrolithiasis.
• Milk of magnesia (magnesium hydroxide) at higher doses acts as an osmotic laxative. Use with caution in renal impairment — magnesium is renally cleared.
• Antacids do not treat the underlying cause of acid-related disease. Patients using antacids more than twice per week for heartburn should be evaluated for GERD or PUD.

Antiemetics

Nausea and vomiting are managed through multiple receptor pathways — and which antiemetic is appropriate depends on the underlying cause. Understanding the mechanism of each drug class guides safe administration and monitoring.

Ondansetron (Zofran) — 5-HT3 antagonist

Ondansetron is the most widely used antiemetic in modern practice. It blocks serotonin (5-HT3) receptors in the GI tract and chemoreceptor trigger zone (CTZ), preventing nausea signals from reaching the vomiting center.

Indications: chemotherapy-induced nausea and vomiting (CINV), post-operative nausea, radiation-induced emesis.

Nursing considerations:

• QT prolongation: Ondansetron prolongs the QT interval, especially at higher IV doses. Obtain baseline ECG in patients with known QT prolongation or electrolyte abnormalities (hypokalemia, hypomagnesemia increase risk). Monitor for dysrhythmias.
• Serotonin syndrome: Risk increases when combined with other serotonergic agents (SSRIs, SNRIs, tramadol, triptans). Monitor for hyperthermia, agitation, tremor, clonus.
• Headache is the most common side effect — educate patients.
• Ondansetron does not cause sedation or extrapyramidal effects (distinguishes it from phenothiazines and metoclopramide).
• IV doses should be administered slowly (over 15–30 minutes) to reduce QT effects.

Promethazine and prochlorperazine — phenothiazines

Phenothiazine antiemetics block dopamine D2 receptors in the CTZ, reducing the trigger for vomiting. They also have antihistamine and anticholinergic properties.

Indications: nausea, vomiting, motion sickness, pre-operative sedation.

Safety concerns — high priority:

• Promethazine IV black box warning: IV promethazine is associated with severe tissue necrosis, gangrene, and limb amputation if extravasation occurs. The FDA has issued a black box warning — IV use is generally avoided in many institutions. Preferred routes are oral, IM, or rectal.
• Extrapyramidal effects (EPS): Dopamine blockade can cause akathisia (restlessness), dystonia (involuntary muscle contractions), pseudoparkinsonism (tremor, rigidity). Treat acute dystonia with diphenhydramine (Benadryl) IV or IM.
• Orthostatic hypotension: Phenothiazines cause significant alpha-adrenergic blockade — monitor blood pressure when patients change positions. Fall precautions are essential.
• Sedation: Heavy sedation is expected — ensure patient safety, especially in older adults. Avoid in patients with CNS depression or respiratory compromise.
• Tardive dyskinesia can occur with long-term use (though less commonly than with metoclopramide).

For context on extrapyramidal effects and dopamine antagonism across drug classes, see the psychiatric medications nursing reference.

Metoclopramide (Reglan) — D2 antagonist and prokinetic

Metoclopramide blocks dopamine D2 receptors in the CTZ (antiemetic effect) and in the GI tract (prokinetic effect). It increases gastric motility, accelerates gastric emptying, and tightens the lower esophageal sphincter.

Indications: nausea/vomiting, gastroparesis, GERD (adjunct).

Black box warning — tardive dyskinesia: Metoclopramide carries a black box warning for tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by repetitive, involuntary movements of the face and extremities. Risk increases significantly with use beyond 12 weeks. Limit use to the shortest effective duration.

Nursing considerations:

• Contraindicated in patients with GI obstruction, perforation, or hemorrhage — prokinetic effects increase peristalsis and worsen these conditions.
• Avoid in Parkinson’s disease — D2 blockade worsens parkinsonian symptoms.
• Extrapyramidal effects (restlessness, akathisia, dystonia) can occur even with short-term use.
• Administer 30 minutes before meals and at bedtime for gastroparesis.
• Monitor for signs of TD: tongue protrusion, lip smacking, grimacing, repetitive limb movements. If observed, discontinue immediately and notify the provider.

Bowel management medications

Bowel management spans a wide spectrum of drugs — from stool softeners that gently ease elimination to stimulant laxatives and osmotic agents. Choosing the right agent requires understanding the mechanism and the clinical context.

Laxatives

Bulk-forming laxatives — psyllium (Metamucil)

Psyllium absorbs water in the intestine, increasing stool bulk and stimulating peristalsis. It acts like dietary fiber. Onset is 12–72 hours.

Nursing priority: psyllium must be taken with at least 8 oz (240 mL) of water. Without adequate fluid, the expanding fiber can cause esophageal or intestinal obstruction. This is a high-yield NCLEX point. Separate from other medications — psyllium can reduce absorption of some drugs.

Osmotic laxatives — polyethylene glycol (Miralax) and lactulose

Osmotic laxatives draw water into the intestinal lumen by osmotic pressure, softening stool and stimulating defecation. Onset is 24–72 hours for PEG, 24–48 hours for lactulose.

• Polyethylene glycol (PEG/Miralax): Well-tolerated, tasteless when mixed in liquid, no significant electrolyte absorption. Monitor for electrolyte imbalances with prolonged use or high-dose bowel prep.
• Lactulose (Enulose, Kristalose): A synthetic disaccharide that is not absorbed — it reaches the colon intact, where bacteria metabolize it into organic acids. This lowers colonic pH and creates an osmotic gradient.
  • Key indication beyond constipation: hepatic encephalopathy. In the colon, lactulose acidifies the environment, which converts ammonia (NH₃) to ammonium (NH₄⁺) — a charged form that cannot be absorbed. This reduces systemic ammonia levels. Target: 2–3 soft stools per day. See hepatic encephalopathy nursing reference for full ammonia management protocols.
  • Lactulose causes bloating, cramping, and gas — educate patients.
  • Excessive use can cause severe diarrhea and electrolyte derangements.

Stimulant laxatives — bisacodyl (Dulcolax), senna (Senokot)

Stimulant laxatives directly stimulate the myenteric nerve plexus, increasing intestinal motility and secretion. Onset: 6–12 hours (oral), 15–60 minutes (rectal).

• Intended for short-term use only. Chronic use causes dependence (“cathartic colon”) and electrolyte imbalances.
• Avoid in electrolyte imbalances — increased motility worsens potassium and sodium losses.
• Bisacodyl tablets are enteric-coated — swallow whole, do not crush. Do not take within 1 hour of antacids or dairy (alkaline environment dissolves the coating prematurely, causing gastric irritation).

Stool softeners — docusate (Colace)

Docusate is a surfactant that lowers the surface tension of stool, allowing water and fat to penetrate and soften it. It does not stimulate peristalsis or increase motility. Onset: 1–3 days.

Clinical indication: Prevention of straining in patients where Valsalva is contraindicated — post-MI, post-cardiac surgery, post-anorectal surgery, increased intracranial pressure.

Docusate is often prescribed together with a stimulant laxative (e.g., docusate + senna) for opioid-induced constipation, since opioids reduce both motility and stool water content.

Antidiarrheals — loperamide (Imodium) and diphenoxylate/atropine (Lomotil)

Both agents reduce intestinal motility by acting on opioid receptors in the GI tract, slowing peristalsis and reducing stool frequency.

Critical contraindication — NCLEX high yield: Antidiarrheals are contraindicated in infectious diarrhea, particularly Clostridium difficile colitis. Slowing bowel motility allows toxin accumulation and can precipitate toxic megacolon — a life-threatening complication. Before administering an antidiarrheal, confirm the diarrhea is not infectious.

Additional nursing considerations:

• Loperamide (Imodium): Does not cross the blood-brain barrier at therapeutic doses — minimal CNS effects. Monitor for abdominal distension, absent bowel sounds, or signs of obstruction. Avoid in bowel obstruction.
• Diphenoxylate/atropine (Lomotil): Diphenoxylate is a controlled substance (Schedule V) due to opioid activity. Atropine is added in sub-therapeutic doses to discourage abuse (causes anticholinergic effects at high doses). Contraindicated in children under 2 years.
• Assess bowel sounds before and during antidiarrheal therapy. Absent bowel sounds suggest ileus — antidiarrheals are contraindicated.
• Monitor fluid and electrolyte status — diarrhea causes significant losses regardless of medication.

For nursing management of inflammatory bowel disease, see Crohn’s disease nursing and ulcerative colitis nursing.

GI motility agents and antispasmodics

Prokinetics — metoclopramide and erythromycin

Prokinetics increase GI motility, accelerate gastric emptying, and are primarily used for gastroparesis — delayed gastric emptying without mechanical obstruction, most commonly seen in diabetic patients and post-surgical patients.

Metoclopramide (discussed fully in the antiemetics section above) is the first-line prokinetic agent for gastroparesis. Administer 30 minutes before meals.

Erythromycin (low dose): At low doses (not antimicrobial), erythromycin acts as a motilin receptor agonist, stimulating gastric contractions and accelerating emptying. It is used short-term in refractory gastroparesis and for gastric ileus in the ICU setting.

• Erythromycin at prokinetic doses is not an antibiotic course — but its antibiotic properties still apply, and it can disrupt gut flora.
• QT prolongation risk is present with erythromycin — monitor ECG in at-risk patients.
• Tolerance develops rapidly with erythromycin (typically within 4 weeks), limiting long-term use.
• Assess bowel sounds before administration. Contraindicated if obstruction is suspected.
• For nursing management of pancreatitis and NPO status in GI patients, see pancreatitis nursing reference.

Antispasmodics — dicyclomine (Bentyl) and hyoscyamine (Levsin)

Antispasmodics are anticholinergic agents that reduce GI smooth muscle spasm. They are primarily prescribed for irritable bowel syndrome (IBS), biliary colic, and functional GI cramping.

Mechanism: Block muscarinic (M1, M2) acetylcholine receptors in smooth muscle → reduce intestinal contractions and cramping.

Nursing considerations — anticholinergic effects:

The SLUDGE mnemonic describes muscarinic stimulation: Salivation, Lacrimation, Urination, Defecation, GI motility, Emesis. Antispasmodics produce the opposite of these effects. Nurses must monitor for:

• Dry mouth (xerostomia)
• Urinary retention — particularly dangerous in men with benign prostatic hyperplasia (BPH)
• Constipation — worsens pre-existing constipation
• Blurred vision / mydriasis — patient safety concern; do not drive
• Tachycardia — from vagal blockade
• CNS effects — especially in older adults: confusion, hallucinations, agitation (anticholinergic toxicity)

Contraindications: GI obstruction, urinary retention, narrow-angle glaucoma, myasthenia gravis.

Patient teaching: These drugs cause dry mouth — encourage sugarless candy or ice chips. Avoid operating heavy machinery due to blurred vision and sedation. Report inability to urinate.

H. pylori treatment

H. pylori is a gram-negative organism colonizing the gastric mucosa — responsible for the majority of peptic ulcers and a significant risk factor for gastric cancer. Eradication requires combination antibiotic therapy alongside acid suppression. The complexity of these regimens makes patient teaching and compliance critical nursing responsibilities. See peptic ulcer disease nursing for full ulcer pathophysiology and nursing management.

Standard regimens

Triple therapy (7–14 days):

• PPI (standard dose, twice daily)
• Clarithromycin 500 mg twice daily
• Amoxicillin 1 g twice daily

First-line when clarithromycin resistance is low (< 15% in the local population). Amoxicillin substitution with metronidazole 500 mg twice daily is used in penicillin-allergic patients.

Quadruple therapy (10–14 days):

• PPI (standard dose, twice daily)
• Bismuth subsalicylate (Pepto-Bismol) 525 mg four times daily
• Metronidazole 500 mg three to four times daily
• Tetracycline 500 mg four times daily

Recommended when clarithromycin resistance is suspected or confirmed, after prior macrolide exposure, or as second-line after triple therapy failure. Also used as first-line in areas with high clarithromycin resistance.

Bismuth-based quadruple therapy is increasingly preferred as first-line in many US guidelines due to rising clarithromycin resistance rates.

Nursing responsibilities for H. pylori treatment

• Allergy verification: Before any amoxicillin-containing regimen, confirm penicillin allergy status. Cross-reactivity between penicillin and amoxicillin is well-established.
• Compliance counseling is essential. Incomplete courses allow resistant organisms to survive — treatment failure is a direct consequence of non-compliance. Frame this clearly to patients: skipping doses is not an option.
• Side effects to anticipate and counsel:
  • Metronidazole: metallic taste, nausea, peripheral neuropathy with extended use. Avoid alcohol for 48 hours after the last dose — severe disulfiram-like reaction (flushing, vomiting, tachycardia).
  • Clarithromycin: GI upset, bitter taste, QT prolongation.
  • Bismuth: black stool, black tongue — reassure patients this is expected and harmless.
  • Tetracycline: photosensitivity, avoid dairy within 1–2 hours (calcium chelation reduces absorption).
• Confirm eradication: H. pylori eradication is confirmed at least 4 weeks after completing therapy (urea breath test or stool antigen test). PPIs must be stopped at least 2 weeks before testing to avoid false-negative results.
• Cirrhosis and H. pylori: Patients with cirrhosis have increased risk of H. pylori-related complications. See cirrhosis nursing for GI complications in liver disease.

NCLEX priority nursing considerations

These are the highest-yield points for pharmacology questions on NCLEX.

Related references

• GERD nursing reference — pathophysiology, LES dysfunction, PPI therapy, Barrett’s esophagus
• Peptic ulcer disease nursing — H. pylori, ulcer types, GI bleed management
• Hepatic encephalopathy nursing reference — lactulose protocol, ammonia monitoring, West Haven staging
• Pancreatitis nursing reference — NPO management, pain control, GI rest
• Crohn’s disease nursing — inflammatory bowel disease, steroid use, nutrition
• Ulcerative colitis nursing — bowel management, surgical interventions
• Bowel obstruction nursing — antidiarrheal contraindications, NG tube management
• Cirrhosis nursing — portal hypertension, GI complications
• Cardiovascular medications nursing — clopidogrel interactions
• Psychiatric medications nursing — extrapyramidal effects, D2 blockade across drug classes